Information Provided By: 
Fly News Breaks for December 3, 2015
HZNP
Dec 3, 2015 | 08:01 EDT
Morgan Stanley analyst David Risinger resumed coverage on Horizon Pharma with an Underweight rating and $23 price target on shares. Risinger expects greater payer pressures on primary care business volume and net price and believes Actimmune for FA is a long shot and did not include it in his sales model.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
